RT Journal Article
SR Electronic
T1 Information leaflets for patients with hepatitis C receiving treatment with triple therapy
JF European Journal of Hospital Pharmacy: Science and Practice
JO Eur J Hosp Pharm
FD British Medical Journal Publishing Group
SP 13
OP 19
DO 10.1136/ejhpharm-2012-000176
VO 20
IS 1
A1 Inés Yeste-Gómez
A1 Carmen Guadalupe Rodríguez-González
A1 Álvaro Giménez-Manzorro
A1 Arantza Ais-Larisgoitia
A1 María Sanjurjo-Saez
YR 2013
UL http://ejhp.bmj.com/content/20/1/13.abstract
AB The NS3/4 protease inhibitors boceprevir and telaprevir in conjunction with peginterferon α and ribavirin (triple therapy) increase the rate of a sustained virological response in patients with genotype-1 chronic hepatitis C but, to achieve a successful result, good compliance is vital. As part of a pharmaceutical care programme, in the Outpatient Pharmacy we developed information leaflets to help patients understand the objectives of triple therapy, to be aware and prevent the possible side effects and to teach patients how to take the medicines.